Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients ...

A randomized controlled trial finds no clear benefit of adding bezlotoxumab to FMT in patients with IBD and recurrent C difficile infection.

The biomarker assay can be used potentially to enrich clinical trials and monitor patients' disease activity and treatment response.

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients ...

Aeglea Biotherapeutics Inc. ( (SYRE) ) has released its Q3 earnings. Here is a breakdown of the information Aeglea Biotherapeutics Inc.

Abu Dhabi, UAE: Sheikh Shakhbout Medical City (SSMC), one of the UAE’s largest hospitals for serious and complex care and a ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

As people live longer than ever before, the incidence of aging-related, chronic diseases is on the rise, severely impacting ...

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error ...

Mirikizumab, a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis, ...

Researchers used pharmacovigilance data to examine the onset of gastrointestinal adverse events associated with the use of biologic therapies for psoriasis.

Thetis Pharmaceuticals Announces Positive Initial Results From a Phase 1a Study of TP-317, a BLT1 Agonist, in Healthy ...